News Image

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Provided By GlobeNewswire

Last update: May 8, 2025

Topline data from multiple Phase 2 studies expected throughout 2025

 Q2 readout from VTX3232 study in patients with early Parkinson’s disease

Read more at globenewswire.com

VENTYX BIOSCIENCES INC

NASDAQ:VTYX (9/26/2025, 8:00:02 PM)

After market: 2.98 0 (0%)

2.98

+0.29 (+10.78%)



Find more stocks in the Stock Screener

Follow ChartMill for more